register

News & Trends - Pharmaceuticals

Building bridges to medical innovation: Amgen’s industry partnership fuels commercialisation success

Health Industry Hub | May 24, 2023 |

In an interview on Health Industry Hub, Professor Lyn Griffiths, Program Director for the Bridge Program at Queensland University of Technology (QUT), and Gabi Mittas, General Manager of Amgen in Australia and New Zealand, discussed the importance of ongoing industry partnerships in driving the success of the Bridge Program.

The program, now in its seventh year, focuses on bridging the gap between medical research and commercialisation. It aims to equip mid-career researchers with the necessary skills, knowledge, and industry connections to effectively translate their research into real-world applications. With the support of industry leaders like Amgen, the program has seen remarkable results.

During the interview, Professor Griffiths highlighted some of the key challenges faced by Australian researchers, including the issues in translating research into tangible outcomes. She emphasised the need for funding, networks, and strategies to support researchers in the commercialisation process. Professor Griffiths also highlighted the importance of nurturing talented researchers and creating pathways to retain them in Australia.

Ms Mittas shared Amgen’s commitment to supporting the Bridge Program since its inception. She emphasised the significance of bringing innovation to patients in need and the importance of providing participants with the skills and resources required for successful commercialisation. Amgen’s involvement includes financial support, keynote speakers, and a three-day symposium, showcasing the company’s dedication to the program’s goals.

The launch of this year’s Bridge Program at the Amgen offices in Sydney was a resounding success. Notable highlights included the presence of The Hon. Ed Husic MP Minister for Industry and Science, who reaffirmed the government’s support for initiatives like the Bridge Program. The event also provided an opportunity for participants to interact with industry leaders, gain insights into career paths, and foster meaningful connections.

The ongoing collaboration between academia, industry, and the government in programs like the Bridge Program exemplifies the collective effort to bridge the gap between research and commercialisation. Through continued industry support and targeted training, Australia aims to strengthen its position in innovation outputs, bringing vital medical advancements to patients and positively impacting lives.

Covering the scientific, legal, financial, clinical, regulatory and reimbursement elements of the commercialisation process, the Bridge Program benefits from a consortium of leading partners including AbbVie, Amgen, Australian National University, Pfizer, Roche, Spruson & Ferguson, University of New South Wales, University of Western Australia and the Government of Western Australia. The program is supported by the Federal Government through MTPConnect, with industry-matched funding from consortium members.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.